Impact of C-reactive protein point-of-care testing on antibiotic prescriptions for children and adults with suspected respiratory tract infections in primary care: a French patient-level randomized controlled superiority trial
Camille Jung, Corinne Lévy, Stéphane Béchet, Philippe Aegerter, Robert Cohen, Robert Touitou, Touitou Robert, Batsch Esther, Casadevall Marion, Chevillard Marie, Denantes Mady, Djen David, Gasman Yaël, Janody Valérie, Lancelot Anne, Laplante Alice, Levy Dora, M E Vrouenraets Saskia, Myara François, Pinto Emmanuel, Trincard Blandine, Y. Jacques, Nureni-Banafunzi Ismaël, Lachine Nastassja, Dardel Nicole, Faure David, Chefdebien Marine, R. Tende Nzengou Richard, Lion-Altmayer Juliette, Gaisne-Joly Marine, Zaghdoun David, G Florence
Abstract
OBJECTIVES: The value of C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescriptions in adults has previously been emphasized. The aim of this study was to assess the impact of CRP POCT on antibiotic prescriptions by general practitioners (GPs) for suspected lower respiratory tract infections in children ≥3 years old and in adults. METHODS: This was an open-label randomized trial (NCT03540706) conducted in 26 GPs in France between October 2019 and March 2023. Of the 404 participating patients, 207 (51.2%) were randomized to the CRP POCT group and 197 (48.8%) to the control group (i.e. no CRP POCT). During consultations, GPs measured CRP levels in patients randomized to the CRP POCT group. The primary endpoint was the proportion of patients in each group who were prescribed antibiotics by their GP during the consultation. Z-tests were used for comparisons. RESULTS: The overall proportion of patients treated with antibiotics was similar in the CRP POCT (n = 89/207, 43% CI: 36.2, 50.0) and in the control group (n = 94/197, 47.7% CI: 40.6, 54.9), difference: -4.7 CI: -14.4, 5.0; p 0.3. Overall, 75% of the GPs followed CRP-based antibiotic prescription recommendations in the CRP POCT group. DISCUSSION: CRP POCT did not reduce antibiotic prescriptions in this trial.